Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220
Debt
Debt-to-Equity RatioN/A
Current Ratio10.86
Quick Ratio10.86
Price-To-Earnings
Trailing P/E Ratio-11.57
Forward P/E Ratio-9.62
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.50 per share
Price / Book8.63
Profitability
EPS (Most Recent Fiscal Year)($2.61)
Net Income$-131,320,000.00
Net MarginsN/A
Return on Equity-64.95%
Return on Assets-58.54%
Miscellaneous
Employees131
Outstanding Shares58,020,000
Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.21. During the same period in the prior year, the business earned ($0.52) earnings per share. View Aimmune Therapeutics' Earnings History.
What price target have analysts set for AIMT?
8 equities research analysts have issued 1-year price objectives for Aimmune Therapeutics' shares. Their predictions range from $30.00 to $80.00. On average, they expect Aimmune Therapeutics' share price to reach $56.1263 in the next year. View Analyst Ratings for Aimmune Therapeutics.
What are Wall Street analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (5/11/2018)
- 2. Cantor Fitzgerald analysts commented, "A stock now perhaps better suited for investors than traders. In our view, the investment profile for AIMT stock changed significantly once top-line data from the Phase 3 PALISADE trial were released. Aside from the company’s IPO, maybe, the data release constitutes the most important event in the company’s history, we believe. Although AIMT plans to develop other treatments, because peanut allergy is the most prevalent food allergy, the NPV of additional therapies is probably lower than that of AR101. We suspect, too, that the market may discount a higher pTS for other programs now that POC has been established." (5/9/2018)
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), HUTCHISON CHINA/S (HCM) and Ultragenyx Pharmaceutical (RARE).
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Dr. Stephen George Dilly, Pres, CEO & Director (Age 58)
- Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 58)
- Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)
- Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 51)
- Dr. Daniel C. Adelman, Chief Medical Officer (Age 61)
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.
Has Aimmune Therapeutics been receiving favorable news coverage?
Media headlines about AIMT stock have trended somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a news sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Aimmune Therapeutics' major shareholders?
Aimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.31%), Eventide Asset Management LLC (2.70%), Eagle Asset Management Inc. (2.41%), Palo Alto Investors LP (2.34%), Point72 Asset Management L.P. (1.86%) and Carillon Tower Advisers Inc. (1.66%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.
Which institutional investors are selling Aimmune Therapeutics stock?
AIMT stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., TLP Group LLC, Point72 Asset Management L.P., Rock Springs Capital Management LP, New York State Common Retirement Fund, Barclays PLC and Citigroup Inc.. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly and Susan E Barrowcliffe. View Insider Buying and Selling for Aimmune Therapeutics.
Which institutional investors are buying Aimmune Therapeutics stock?
AIMT stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Loomis Sayles & Co. L P, Eventide Asset Management LLC, BlackRock Inc., Massachusetts Financial Services Co. MA, Palo Alto Investors LP, Spark Investment Management LLC and Foresite Capital Management III LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.
How do I buy shares of Aimmune Therapeutics?
Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $30.20.
How big of a company is Aimmune Therapeutics?
Aimmune Therapeutics has a market capitalization of $1.79 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe.
How can I contact Aimmune Therapeutics?
Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]
MarketBeat Community Rating for Aimmune Therapeutics (AIMT)
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
